Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nexstim

9.60 EUR0.00 %25.9, 11.27
5,688 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
0.00 %
+4.80 %
-2.64 %
+6.67 %
-32.39 %
-28.62 %
+236.84 %
+110.99 %
-98.41 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
77.52M EUR
Turnover
17.44K EUR
P/E (adj.) (26e)
117.31
EV/EBIT (adj.) (26e)
58.26
P/B (26e)
7.85
EV/S (26e)
5.46
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.00 EUR
Updated
16.08.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 17.08.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
3rd party
ShowingAll content types

Forum discussions
From initial introduction to actual delivery of a system to a neurosurgical hospital, it typically takes between one and two years, with an average of about 18 months. It is usually more than a year because this is a budgetary item for the hospital. If a hospital gets interested ...
22 hours ago
by Kyhnykeisari
16
Interview with Sinaptica’s Mariash: https://www.youtube.com/watch?v=9Ps5TPuQjN8 There probably wasn’t anything new in the first half, but the latter part paints a picture of the future beyond Alzheimer’s as well, for those interested. Nexstim is also mentioned, all visibility is ...
9/23/2026, 6:55 AM
by AccionHombre
14
And in Brainlab’s case, it is good to remember that, unlike Nexstim, Brainlab is already geographically almost everywhere. “We are also adding other markets. We have approvals in, among others, Canada, Australia, the UK, India, Malaysia and the United Arab Emirates, and we are seeking...
22 hours ago
12
Analyst Group Interview with Nexstim’s CEO Mikko Karvinen | Nexstim | Analyst Group Intervju på Nexstim.
23 hours ago
by Kyhnykeisari
10
What is meaningful for the introduction of the treatment in Finland is cost savings, and in the US, insurance reimbursement. If it were calculated that Sinaptica’s treatment would keep an Alzheimer’s patient at home for several years, this form of treatment would spread very quickly...
9/21/2026, 1:12 PM
by Jatast
9
“We have known about TMS treatment for a long time, but the interesting thing about the navigated version is that it hits very precisely and thus turns out to be more effective and with fewer side effects. This is particularly relevant in courses of treatment where repeated (repetitive...
2 hours ago
by Kyhnykeisari
7
That’s right, the agreement is still in preparation and is intended to be signed by the end of this year. It’s quite possible that not much will be communicated outwardly, and we will instead see the realization in the earnings reports. Sinaptica’s product could potentially be on...
9/21/2026, 9:31 AM
by AccionHombre
7
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.2
2027

Annual report '26

Press release04.09.2026, 08.00

European University Hospital Orders Nexstim NBS 6 System

Nexstim
Press release03.09.2026, 08.00

Nordic Private Clinic Expands Use with Additional NBS 6 System

Nexstim
Third party research02.09.2026, 08.11

Nexstim: Stimulating growth with surgical accuracy; INITIATE with BUY - NuWays AG Research

Nexstim is a Finnish MedTech company and a global leader in navigated transcranial magneticstimulation (nTMS) technology. With nTMS, Nexstim helps (i) surgeons preserve patients' motor and speech cortices and (ii) clinicians treat neurological and psychiatric...

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release02.09.2026, 08.00

US University Customer Purchases Nexstim NBS 6 for Research Purposes

Nexstim
Press release01.09.2026, 08.00

European Hospital Orders Nexstim NBS 6 System

Nexstim
Press release21.08.2026, 08.00

Nexstim Receives NBS 6 System Order for a European hospital and existing Nexstim customer

Nexstim
Regulatory press release20.08.2026, 12.00

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim
Press release19.08.2026, 08.00

Nexstim Receives NBS 6 Therapy System Order from New US Customer

Nexstim
Nexstim H1'26: Brainlab potential to be weighed later this year
Research17.08.2026, 09.09 by
Antti Siltanen

Nexstim H1'26: Brainlab potential to be weighed later this year

Concrete evidence of the Brainlab collaboration's potential will be available during the rest of the year.

Nexstim
Regulatory press release14.08.2026, 08.00

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2026 (UNAUDITED)

Nexstim
Press release11.08.2026, 08.00

Notice of Nexstim Plc’s Half-Year Report H1 2026

Nexstim
Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate
Analyst Comment11.08.2026, 08.25 by
Antti Siltanen

Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate

We expect the dip in recurring revenue to have weighed on earnings.

Nexstim
Press release31.07.2026, 12.00

Finnish Private Clinic Group Orders Additional Nexstim NBS 6 System

Nexstim
Regulatory press release20.07.2026, 12.00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Press release17.07.2026, 08.00

Delve Psychiatry Upgrades to Nexstim's Latest NBS 6 Platform

Nexstim
Press release15.07.2026, 08.00

Nexstim Receives NBS 6 Therapy System Order from a Neurology Clinic in the United States

Nexstim
Nexstim received another order for ten NBS 6 systems
Analyst Comment15.07.2026, 08.01 by
Frans-Mikael Rostedt

Nexstim received another order for ten NBS 6 systems

The second order for ten systems within a month indicates the rapid scaling of the distribution partnership.

Nexstim
Press release14.07.2026, 08.00

Nexstim Receives a New Order for Ten NBS 6 Systems from Distributor

Nexstim
Press release10.07.2026, 08.00

Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications

Nexstim
Press release08.07.2026, 08.00

Nexstim Secures First NBS 6 Sale Following Malaysian Market Authorization

Nexstim